Trials / Recruiting
RecruitingNCT03342144
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Conditions
Timeline
- Start date
- 2017-12-04
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2017-11-14
- Last updated
- 2025-12-08
Locations
70 sites across 3 countries: Austria, Germany, Switzerland
Source: ClinicalTrials.gov record NCT03342144. Inclusion in this directory is not an endorsement.